EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.
EML4-NTRK3 Fusion Cervical Sarcoma: A Case Report and Literature Review.
复制标题
EML4-NTRK3融合宫颈肉瘤：病例报告和文献综述。
DOI：
10.3389/fmed.2022.832376
复制
发表时间：
2022
影响因子：
3.9
通讯作者：
中科院分区：
文献类型：
--
作者：
神经营养因子酪氨酸激酶受体（NTRK）融合瘤的概念是近年来出现的。此外，NTRK融合在常见肿瘤中是不常见的，但通常可以在罕见肿瘤中发现。NTRK融合宫颈或子宫肿瘤主要通过病例报告认识，因为其发生率极低。在这项研究中，我们报告了一个新的情况下，EML 4-NTRK 3融合宫颈肉瘤，以提高其认识。据我们所知，这是第一例来自中国机构的病例。我们还进行了文献回顾，共检索到19例NTRK融合宫颈肿瘤和4例子宫肿瘤。我们总结这些病例的临床病理特征、治疗方法及预后。根据现有资料，我们观察到手术和完全切除，如果可能的话，仍然是主要的治疗方式。此外，越来越多的研究表明，原肌球蛋白受体激酶（TRK）抑制剂可以改善NTRK基因融合的癌症患者的预后，这给转移性病变患者带来了银。单因素生存分析发现年龄和核分裂率可能与复发或转移有关。为了得出更令人信服的结论，有必要建立一个罕见病例的国际数据库，并汇总这些散发病例。
The concept of neurotrophic factor tyrosine kinase receptor (NTRK) fusion tumor has emerged in recent years. Moreover, NTRK fusion is unusual in common tumors but can often be identified in rare tumors. The NTRK fusion cervical or uterine tumors are mainly recognized through case reports due to their extremely low incidence. In this study, we reported a new case of EML4–NTRK3 fusion cervical sarcoma to enhance its recognition. To the best of our knowledge, this is the first case from a Chinese institution. We also conducted a literature review, in which a total of 19 cases of NTRK fusion cervical tumors and 4 cases of uterine tumors were retrieved. We summarized the clinicopathological features, treatment methods, and prognosis of these cases. Based on available information, we observed that surgery and complete excision, if possible, are still the primary modes of therapy. In addition, an increasing number of studies have shown that tropomyosin receptor kinases (TRK) inhibitors can improve the prognosis of cancer patients with NTRK gene fusion, which gives a silver lining for patients with metastatic lesions. We found that age and mitotic rate may be associated with recurrence or metastasis by univariate survival analysis. To draw more convincing conclusions, there is a need to establish an international database of rare cases and aggregate these sporadic cases.
登录
查看更多内容
DOI：
10.1097/pas.0000000000001055
发表时间：
2018-06
期刊：
The American journal of surgical pathology
影响因子：
--
作者：
Chiang S;Cotzia P;Hyman DM;Drilon A;Tap WD;Zhang L;Hechtman JF;Frosina D;Jungbluth AA;Murali R;Park KJ;Soslow RA;Oliva E;Iafrate AJ;Benayed R;Ladanyi M;Antonescu CR
通讯作者：
Antonescu CR
DOI：
10.1016/j.annonc.2020.08.2232
发表时间：
2020-11
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Demetri GD;Antonescu CR;Bjerkehagen B;Bovée JVMG;Boye K;Chacón M;Dei Tos AP;Desai J;Fletcher JA;Gelderblom H;George S;Gronchi A;Haas RL;Hindi N;Hohenberger P;Joensuu H;Jones RL;Judson I;Kang YK;Kawai A;Lazar AJ;Le Cesne A;Maestro R;Maki RG;Martín J;Patel S;Penault-Llorca F;Premanand Raut C;Rutkowski P;Safwat A;Sbaraglia M;Schaefer IM;Shen L;Serrano C;Schöffski P;Stacchiotti S;Sundby Hall K;Tap WD;Thomas DM;Trent J;Valverde C;van der Graaf WTA;von Mehren M;Wagner A;Wardelmann E;Naito Y;Zalcberg J;Blay JY
通讯作者：
Blay JY
影响因子：
3.3
作者：
Klopp, Ann;Smith, Benjamin D;Alektiar, Kaled;Cabrera, Alvin;Damato, Antonio L;Erickson, Beth;Fleming, Gini;Gaffney, David;Greven, Kathryn;Lu, Karen;Miller, David;Moore, David;Petereit, Daniel;Schefter, Tracey;Small, William Jr;Yashar, Catheryn;Viswanathan, Akila N
通讯作者：
Viswanathan, Akila N
DOI：
10.1038/s41571-018-0113-0
发表时间：
2018-12
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Cocco E;Scaltriti M;Drilon A
通讯作者：
Drilon A
影响因子：
28.2
作者：
Drilon A;Siena S;Ou SI;Patel M;Ahn MJ;Lee J;Bauer TM;Farago AF;Wheler JJ;Liu SV;Doebele R;Giannetta L;Cerea G;Marrapese G;Schirru M;Amatu A;Bencardino K;Palmeri L;Sartore-Bianchi A;Vanzulli A;Cresta S;Damian S;Duca M;Ardini E;Li G;Christiansen J;Kowalski K;Johnson AD;Patel R;Luo D;Chow-Maneval E;Hornby Z;Multani PS;Shaw AT;De Braud FG
通讯作者：
De Braud FG